Aimmune Therapeutics
AIMT
AIMT was delisted on the 12th of October, 2020.
0 hedge funds and large institutions have $0 invested in Aimmune Therapeutics in 2020 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 188 closing their positions.
100% less funds holding
Funds holding: 188 → 0 (-188)
100% less funds holding in top 10
Funds holding in top 10: 9 → 0 (-9)
100% less capital invested
Capital invested by funds: $1.49B → $0 (-$1.49B)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 188
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$143M |
| 2 |
BlackRock
New York
|
-$129M |
| 3 |
PCM
Pentwater Capital Management
Naples,
Florida
|
-$86.2M |
| 4 |
Goldman Sachs
New York
|
-$75.8M |
| 5 |
AAM
Alpine Associates Management
Palm Beach,
Florida
|
-$71.5M |
AIMT Hedge Fund Activity: Q4 2020 in Review
0 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Aimmune Therapeutics (AIMT) for Q4 2020, worth a combined $0 — down 100% from $1.49B a quarter earlier.
Sellers outnumbered buyers: 188 funds closed out of AIMT and 0 opened new positions — a net loss of 188 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Vanguard Group, exiting entirely with an estimated $143M sold.
- 0 institutional investors held Aimmune Therapeutics (AIMT) as of Q4 2020, down from 188 in Q3 2020.
- Funds reported $0 of Aimmune Therapeutics stock for Q4 2020, down 100% quarter-over-quarter.
- 0 funds opened new Aimmune Therapeutics positions in Q4 2020 and 188 closed out, a net change of -188 holders.
- The largest Aimmune Therapeutics seller in Q4 2020 was Vanguard Group, an estimated $143M sold.
Based on aggregated 13F filings for Q4 2020.